Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Authors

Rachel Sanborn, ProvidenceFollow

Document Type

Presentation

Publication Date

11-4-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Department

Oncology

Comments

SITC Annual Meeting 2023 November 4; San Diego, CA

Recommended Citation

Sanborn, Rachel, "Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors" (2023). Articles, Abstracts, and Reports. 8288.
https://digitalcommons.providence.org/publications/8288